Azenta Earnings Call: Margins Squeezed, Outlook Steady

Azenta, Inc. ((AZTA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Azenta, Inc.’s latest earnings call struck a tone of cautious optimism, as management balanced soft first‑quarter results with confidence in a stronger back half. Executives reiterated margin and cash‑flow ambitions, emphasized a sizable cash balance and buyback capacity, but also acknowledged margin compression, project‑related rework, and macro pressure in key markets.

Total Revenue and Organic Trend

Azenta reported Q1 fiscal 2026 revenue of $149 million, up 1% on a reported basis but down about 1% organically once a roughly 2% foreign‑exchange drag is stripped out. Management framed the print as consistent with a transitional first half, with timing‑related booking shifts weighing on near‑term visibility but not altering full‑year goals.

Strong Cash Position and Capital Authorization

The balance sheet remains a key support for the equity story, with $571 million in cash, cash equivalents, and marketable securities and no debt at quarter‑end, up $25 million sequentially. The Board’s approval of a $250 million share repurchase authorization underlines management’s confidence in long‑term value creation and provides flexibility to offset volatility.

Segment Strengths — Multiomics and Biorepositories

Multiomics revenue reached $67 million and was flat organically, with gains in next‑generation sequencing and gene synthesis helping to offset structural pressure in Sanger sequencing. Sample Management Solutions’ biorepositories posted solid growth, and China was a notable bright spot, delivering 26% organic growth in Multiomics despite broader global caution.

Profitability and Cash Generation (Non‑GAAP)

On a non‑GAAP basis, Azenta delivered earnings per share of $0.09 and adjusted EBITDA of roughly $13 million, translating to an 8.5% margin amid pressure from underutilized capacity and remediation costs. Free cash flow, including the soon‑to‑be‑divested B Medical unit, was a healthy $15 million, supporting the firm’s self‑funded investment and buyback plans.

Reaffirmed Full‑Year Guidance

Management reaffirmed fiscal 2026 targets for 3%–5% organic revenue growth and about 300 basis points of adjusted EBITDA margin expansion, implying a meaningful second‑half acceleration. They also reiterated expectations for more than 30% year‑over‑year improvement in free cash flow, underscoring confidence that early‑year margin drag is transitory and addressable.

Operational Improvement Initiatives

Azenta leaned heavily on its operational playbook, highlighting the rollout of the Azenta Business System, Kaizen routines, and a decentralized operating model as levers for productivity. Targeted investments in biorepositories, regionalized gene synthesis, automation, and commercialization are intended to lift throughput and margins as volumes normalize, particularly in higher‑growth regions.

Strategic Portfolio Actions

The company has signed a definitive agreement to sell its B Medical business, which is now treated as discontinued operations and generated a $10 million non‑cash loss tied to assets held for sale. Management also pointed to an active M&A funnel, stressing disciplined capital allocation that prioritizes strategic fit alongside the newly authorized buybacks.

Gross Margin Compression

Gross margin fell to 44.1%, down about 360 basis points year over year, reflecting underutilized lab capacity in North America, an unfavorable regional mix, and elevated rework costs. Management expects these headwinds to ease as volumes recover and process improvements take hold, but investors will be watching closely for evidence of a turn.

Adjusted EBITDA Margin Decline

Adjusted EBITDA margin contracted by roughly 230 basis points to 8.5%, mirroring the gross margin pressure and the impact of nonrecurring items. While executives framed the decline as temporary, the step‑down underscores the execution risk behind the promised 300‑basis‑point margin expansion for the full year.

Automated Stores Quality Issues and Remediation Cost

Quality issues on automated storage projects, involving 18 stores historically, resulted in higher rework expenses and weighed on profitability in the quarter. Remediation is expected to be largely finished by the end of Q2, with a full‑year incremental cost estimated at $3 million–$5 million that should mostly roll off after the first half.

Regional and End‑Market Softness in North America

North America remained a soft spot, as macro‑driven budget constraints and underutilized labs limited volumes and hurt fixed‑cost absorption. A temporary disruption linked to the U.S. government shutdown further complicated bookings and contributed to lumpy performance, leaving the region a key swing factor for the remainder of the year.

Sanger Sequencing Decline

Sanger sequencing revenue declined meaningfully year over year, reflecting longer‑term structural demand pressure as customers continue to shift toward next‑generation platforms. While growth in next‑generation sequencing partially offset the drop, the mix shift highlights the need for continued innovation and portfolio evolution within Azenta’s Multiomics offering.

Foreign Exchange Headwind and Nonrecurring Charges

Foreign exchange shaved roughly 2% off organic results, reminding investors that the company’s global footprint can cut both ways in volatile currency markets. Additional nonrecurring items included about $700,000 in inventory adjustment charges and the previously noted $10 million non‑cash loss tied to assets held for sale, which clouded underlying trends.

First Half Lumpy Performance and Uncertainty

Management described fiscal 2026 as a transitional year, with a slower first half and a planned ramp in the back half driven by improving demand and operational gains. Bookings were affected by timing shifts, and because Azenta does not provide quarterly guidance, investors will need to tolerate near‑term cadence uncertainty while watching order trends and margin progress.

Forward‑Looking Guidance and Outlook

Looking ahead, Azenta expects 3%–5% organic revenue growth for fiscal 2026, with Multiomics in the low‑single‑digit range and Sample Management Solutions in the mid‑single digits, both accelerating in the second half. The targeted 300‑basis‑point adjusted EBITDA margin expansion is slated to come from roughly 200 basis points of gross profit improvement and about 100 basis points from operating‑expense leverage, supported by an anticipated >30% uplift in free cash flow and the optionality of a $250 million buyback.

Azenta’s earnings call painted a picture of a company navigating short‑term margin and demand turbulence while investing for a stronger, more profitable future. For investors, the story now hinges on whether operational fixes, portfolio moves, and a solid balance sheet can translate into the promised second‑half acceleration and sustained value creation.